Turkey Diabetic Retinopathy Market Size & Outlook, 2025-2033
Turkey Diabetic Retinopathy Market Insights
- Based on Reed Intelligence findings, the Turkey Diabetic Retinopathy Market reached USD 48.05 Million in 2024 and is estimated to attain USD 87.92 Million by 2033.
- From 2026 to 2033, the Turkey market is expected to grow at a steady CAGR of 7%.
- Within the By Type category, Proliferative Diabetic Retinopathy dominated in 2024 in terms of market size contribution.
- Over the forecast period, Non-proliferative Diabetic Retinopathy is forecasted to deliver the fastest growth, positioning it as the most lucrative By Type segment.
![Turkey Diabetic Retinopathy Market Size, Share & Growth Analysis By [2033]](https://reedintelligence.com/uploads/charts/turkey-diabetic-retinopathy-market-turkey-by-type-35572.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Turkey accounted for 0.53% of the global Diabetic Retinopathy Market size in 2024.
- By 2033, United States is expected to remain the top global market in terms of size.
- Within Middle East and Africa, United Arab Emirates is forecasted to dominate the regional Diabetic Retinopathy Market size by 2033.
- Egypt will be the fastest-growing market in Middle East and Africa, projected to achieve USD 141.34 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 48.05 Million |
| Market Size In 2033 | USD 87.92 Million |
| Largest segment | Proliferative Diabetic Retinopathy |
| Units | Revenue in USD Million |
| CAGR | 7% (2025-2033) |
| Segmnetation Covered | |
| By Type |
|
| By Treatment Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Turkey Diabetic Retinopathy Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proliferative Diabetic Retinopathy | XX.x | XX.x | XX.x | 28.62 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Non-proliferative Diabetic Retinopathy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Turkey Diabetic Retinopathy Market By Treatment Type 2025-2033 (USD Million)
| By Treatment Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-VEGF Drug | XX.x | XX.x | XX.x | 19.35 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Steroid Implants | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Laser Surgeries | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Vitrectomy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
